ASBM Commends FDA for Approval, Clear Naming of First Biosimilar

March 9, 2015

  ASBM Commends FDA for Approval, Clear Naming of First Biosimilar For Immediate Release: March 6, 2015 WASHINGTON – The Alliance for Safe Biologic Medicines today commended the U.S. Food and Drug Administration (FDA) on its approval of the first biosimilar to be available for sale in the U.S. market. Approval of Novartis’ Zarxio (filgrastim-sndz), […]

Read More


ASBM European Survey Presented to Italian Ministry of Health

October 23, 2014

Launches discussion about the future of biosimilars in Italy Results from a survey of 470 European physicians conducted by the Alliance for Safe Biologic Medicines (ASBM) set the stage for a stakeholder meeting at the Italian Ministry of Health to discuss the future of biosimilars policy in Italy. The October 20th event, titled “Biosimilars in […]

Read More


ASBM Presents at WHO Meeting on Naming

October 17, 2014

Introduces Chairman Gewanter, shows support for BQ proposal Geneva – The Alliance for Safe Biologic Medicines (ASBM) presented at the World Health Organization’s (WHO) 59th International Nonproprietary Naming Stakeholders Session on Tuesday, October 14, 2014. This was the third time ASBM presented to the WHO but the first appearance for ASBM’s new chairman Dr. Harry […]

Read More


ASBM Names Harry L. Gewanter, MD as Incoming Chairman; Dean Philip Schneider as International Advisory Board Chair

August 7, 2014

ARLINGTON, VA – Michael Reilly, executive director of the Alliance for Safe Biologic Medicines (ASBM) today announced pediatric rheumatologist and current ASBM International Advisory Board (IAB) member, Harry L. Gewanter, MD, FAAP, FACR as ASBM’s incoming chairman. In addition, Philip Schneider, MS, FASHP, Professor and Associate Dean at the University of Arizona, College of Pharmacy […]

Read More


Massachusetts Governor Signs Pharmacy Legislation Creating a Pathway for Biosimilars

June 24, 2014

Arlington, VA – Today, Governor Deval Patrick enacted biosimilars legislation updating Massachusetts’s pharmacy law and paving the way for the substitution of biosimilars deemed ‘interchangeable’ by the Food and Drug Administration (FDA).  The Governor took such action after swift passage of HB 3724 in both chambers of the General Court of the Commonwealth of Massachusetts. […]

Read More


Indiana Governor Signs Biosimilars Legislation Ensuring Patient Safety

March 25, 2014

Arlington, VA – Today, the Alliance for Safe Biologic Medicines (ASBM) applauds Governor Mike Pence of Indiana in signing legislation to ensure the safe substitution of interchangeable biologic medicines, approved by the Food and Drug Administration (FDA). “We commend Indiana in taking the lead to make patient safety the priority as life-altering biologics become more […]

Read More


ASBM Presents New European Survey Findings on Biosimilars and the Importance of Nonproprietary Naming

November 22, 2013

Dublin, Ireland – The Alliance for Safe Biologic Medicines (ASBM) today released the results of a new survey on European physicians’ views on biosimilar naming. ASBM Executive Director Michael Reilly presented the findings at the Drug Information Association (DIA) Biosimilars Workshop in Dublin, Ireland. The key findings showed that nonproprietary names matter to patient safety. […]

Read More


ASBM Presents at WHO Meeting on Naming in Geneva

October 22, 2013

ASBM Presents at WHO Meeting on Naming in Geneva Calls for Distinct Non-Proprietary Names to Ensure Patient Safety Geneva, Switzerland – The Alliance for Safe Biologic Medicines (ASBM) today presented at the World Health Organization’s (WHO) 57th Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances in Geneva, Switzerland. During his presentation, ASBM Chairman, Richard […]

Read More


IAPO Mexico City Meeting Includes Discussion on Biosimilars

September 23, 2013

On September 23rd, in Mexico City, the International Alliance of Patients’ Organizations (IAPO) hosted a discussion on biosimilars at their Latin American Multi-Stakeholder Seminar.  The meeting was attended by patient and interest groups from the region as well as ASBM Executive Director, Michael Reilly, and Global Colon Cancer Association (GCCA) Co-Executive Director, Andy Spiegel. The discussion […]

Read More


The Alliance for Safe Biologic Medicines Statement on the Need for Unique Names for All Biologic Medicines

September 20, 2013

WASHINGTON, DC – Alliance for Safe Biologic Medicines (ASBM) chairman, Richard Dolinar M.D., added a physician’s perspective to the ongoing discussion around the naming of biologic medicines, including biosimilars. “Biologics are highly sensitive to the manufacturing process and their environment; slight differences can have unexpected results,” stated Dolinar. “As a physician, patient safety is paramount. […]

Read More